CDKN2A and cancer: A compelling argument can be made, however, to counter these misperceptions and support a strong pursuit of ARF-based cancer therapies: 1) With the number of p53-independent functions of ARF identified, there is a clear need to focus on developing therapies specifically targeting ARF-mediated pathways.